weekly_roundup

BioTechSign Daily Catalyst Roundup - November 03, 2026

Top BioTechSign catalyst names today: UCBNV, TOI, CMPX, EIKN, ZBIO, INO. FDA, clinical trial, grade-change, dilution, and sentiment signals.

BiotechSign AnalysisNovember 3, 2026

Daily Biotech Catalyst Digest: November 03, 2026

UCBNV leads the current BioTechSign screen at 99.5/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.

Top Catalyst Scores

TickerCompanyScoreGradeStrongest Inputs
UCBNVUCB SA99.5Aclinical activity 100%, publication signal 75%
TOIThe Oncology Institute, Inc.86.6Apublication signal 100%, clinical activity 100%, dilution risk 65%
CMPXCompass Therapeutics, Inc.86.5Aclinical activity 100%, short interest 90%, dilution risk 43%
EIKNEikon Therapeutics, Inc.85.3Aclinical activity 100%, short interest 70%, dilution risk 45%
ZBIOZenas BioPharma, Inc.83.4Aclinical activity 100%, short interest 90%, dilution risk 29%
INOInovio Pharmaceuticals, Inc.82.4Adilution risk 87%, short interest 70%

Recent Grade-Change Queue

  • UCBNV (UCB SA) currently grades A with a 99.5/100 catalyst score. Main inputs: clinical activity 100%, publication signal 75%.
  • SNY (Sanofi SA) currently grades B with a 72.9/100 catalyst score. Main inputs: clinical activity 100%, dilution risk 12%, short interest 10%.
  • QURE (uniQure NV) currently grades D with a 38.7/100 catalyst score. Main inputs: dilution risk 52%, short interest 50%, PDUFA timing 35%.
  • PBYI (Puma Biotechnology Inc) currently grades B with a 79.7/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, short interest 50%.
  • OPK (OPKO Health, Inc.) currently grades B with a 68.0/100 catalyst score. Main inputs: clinical activity 83%, short interest 50%, dilution risk 27%.
  • ICLR (ICON plc) currently grades C with a 51.2/100 catalyst score. Main inputs: clinical activity 100%, dilution risk 10%, short interest 10%.
  • IOVA (Iovance Biotherapeutics) currently grades C with a 58.2/100 catalyst score. Main inputs: clinical activity 67%, short interest 50%, dilution risk 35%.
  • EYPT (EyePoint, Inc.) currently grades C with a 50.4/100 catalyst score. Main inputs: short interest 70%, dilution risk 43%.

What To Watch

Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.